U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07145385) titled 'Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer' on June 27.
Brief Summary: Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition
Study Start Date: Sept., 2025
Study Type: OBSERVATIONAL
Condition:
Retrospective Cohort of Patients Diagnos...